IDEXX LaboratoriesFRA:IX1 +1.38%96 Altman Z-Score is 20.00 as of Jun. 27, 2026, which is 33% above its 10-year median of 15.05. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €554.46 (Modestly Undervalued). Among 204 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 96.08% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 19.77 is strong.
IDEXX Laboratories has a Altman Z-Score of 20.00, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for IDEXX Laboratories's Altman Z-Score or its related term are showing as below:
FRA:IX1'
s Altman Z-Score Range Over the Past 10 Years
Min: 5.58 Med: 15.05 Max: 23.93
Current: 19.77
During the past 13 years, IDEXX Laboratories's highest Altman Z-Score was 23.93. The lowest was 5.58. And the median was 15.05.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
IDEXX Laboratories Altman Z-Score Related Terms
IDEXX Laboratories Altman Z-Score Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IX1 vs A, WAT, NTRA: Altman Z-Score Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Altman Z-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
IDEXX Laboratories's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.0456
+
1.4
*
1.9703
+
3.3
*
0.4135
+
0.6
*
24.1981
+
1.0
*
1.305
=
20.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
IDEXX Laboratories (FRA:IX1) has a Altman Z-Score of 20.00 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on IDEXX Laboratories and its competitors. This is 33% above median its historical median of 15.05. Over the past decade, IDEXX Laboratories' Altman Z-Score has ranged from 5.58 to 23.93. According to the industry distribution chart, IDEXX Laboratories ranks #8 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 3.9%.
Is IDEXX Laboratories' Altman Z-Score too high?
IDEXX Laboratories' current Altman Z-Score of 20.00 is 33% above median its 10-year median of 15.05. Over the past 10 years, this metric has ranged from a low of 5.58 to a high of 23.93. The Medical Diagnostics & Research industry median Altman Z-Score is 2.40. IDEXX Laboratories' value of 20.00 is 735.1% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #8 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Altman Z-Score compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #8 out of 204 companies for Altman Z-Score. This places IDEXX Laboratories in the top 4% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.40. IDEXX Laboratories' value of 20.00 is 735.1% above this benchmark. Historically, IDEXX Laboratories' own Altman Z-Score has ranged from 5.58 to 23.93 over the past decade. While the company's 10-year median is 15.05 vs. the industry median of 2.40, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Diagnostics & Research company?
The median Altman Z-Score among Medical Diagnostics & Research companies is 2.40, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current Altman Z-Score of 20.00 is 735.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z-Score is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current Altman Z-Score is 20.00, which is 33% above median its own 10-year median of 15.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €554.46, compared to a current price of €484.70 — trading 12.6% below its estimated fair value. The current Altman Z-Score is 20.00, which is 33% above median its 10-year median of 15.05 and 735.1% above the Medical Diagnostics & Research industry median of 2.40. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Altman Z-Score is 20.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €484.70 is trading 12.6% below its estimated GF Value™ of €554.46.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
Altman Z-Score: 20.00 (33% above median its 10-year median of 15.05)
GF Value™: €554.46 vs. price of €484.70 (12.6% below fair value)
Industry Position: 735.1% above the Medical Diagnostics & Research median (#8 of 204)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
